The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)
Official Title: A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)-Associated Osteomalacia
Study ID: NCT02304367
Brief Summary: The primary objectives of this study are to evaluate the effect of burosumab treatment on: * Increasing serum phosphorus levels in adults with TIO or ENS-associated osteomalacia * Improvement in TIO/ENS-associated osteomalacia as determined by osteoid thickness (O.Th), osteoid surface/bone surface (OS/BS), osteoid volume/bone volume (OV/BV) and mineralization lag time (MLt).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Colorado Center for Bone Research at Panorama Orthopedics and Spine Center, Golden, Colorado, United States
Yale University School of Medicine, New Haven, Connecticut, United States
Indiana University Hospital, Indianapolis, Indiana, United States
Johns Hopkins University, Baltimore, Maryland, United States
Mayo Clinic, Rochester, Minnesota, United States
Duke University, Durham, North Carolina, United States
Houston Methodist Research Institute, Houston, Texas, United States
Name: Medical Director
Affiliation: Ultragenyx Pharmaceutical Inc
Role: STUDY_DIRECTOR